EP4249476A4 - Sel de composé benzothiazole, forme cristalline et son utilisation - Google Patents

Sel de composé benzothiazole, forme cristalline et son utilisation

Info

Publication number
EP4249476A4
EP4249476A4 EP21893791.0A EP21893791A EP4249476A4 EP 4249476 A4 EP4249476 A4 EP 4249476A4 EP 21893791 A EP21893791 A EP 21893791A EP 4249476 A4 EP4249476 A4 EP 4249476A4
Authority
EP
European Patent Office
Prior art keywords
salt
crystal form
benzothiazole compound
benzothiazole
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21893791.0A
Other languages
German (de)
English (en)
Other versions
EP4249476A1 (fr
Inventor
Long Li
Shidong YI
Tianming Wang
Pingyun Chen
Chengxi Yang
Jingyi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Pharmaceutical Research Co Ltd
Sichuan Kelun Pharmaceutical Research Institute Co Ltd
Original Assignee
Sichuan Kelun Pharmaceutical Research Co Ltd
Sichuan Kelun Pharmaceutical Research Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Pharmaceutical Research Co Ltd, Sichuan Kelun Pharmaceutical Research Institute Co Ltd filed Critical Sichuan Kelun Pharmaceutical Research Co Ltd
Publication of EP4249476A1 publication Critical patent/EP4249476A1/fr
Publication of EP4249476A4 publication Critical patent/EP4249476A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EP21893791.0A 2020-11-19 2021-11-09 Sel de composé benzothiazole, forme cristalline et son utilisation Pending EP4249476A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011304450 2020-11-19
PCT/CN2021/129537 WO2022105644A1 (fr) 2020-11-19 2021-11-09 Sel de composé benzothiazole, forme cristalline et son utilisation

Publications (2)

Publication Number Publication Date
EP4249476A1 EP4249476A1 (fr) 2023-09-27
EP4249476A4 true EP4249476A4 (fr) 2025-04-16

Family

ID=81708355

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21893791.0A Pending EP4249476A4 (fr) 2020-11-19 2021-11-09 Sel de composé benzothiazole, forme cristalline et son utilisation

Country Status (6)

Country Link
US (1) US12583829B2 (fr)
EP (1) EP4249476A4 (fr)
JP (1) JP2023550235A (fr)
CN (2) CN116367833B (fr)
AU (1) AU2021381638A1 (fr)
WO (1) WO2022105644A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202400156A (zh) * 2022-05-16 2024-01-01 大陸商四川科倫藥物研究院有限公司 普拉克索長效緩釋製劑及其製備方法
CN115215818B (zh) * 2022-07-26 2023-03-17 山东京卫制药有限公司 一种普拉克索三苯乙酸盐及其药物缓释制剂
WO2025190207A1 (fr) * 2024-03-15 2025-09-18 四川科伦药物研究院有限公司 Cristal de composé, son procédé de préparation et son utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000418A2 (fr) * 2006-06-27 2008-01-03 Sandoz Ag Nouveau procédé de préparation de sel
WO2019036624A1 (fr) * 2017-08-17 2019-02-21 Gu Zi Qiang Agents anti-parkinson de type sels de pamoate de monoamine, leur procédé de préparation et d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572485D1 (en) * 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
CN102784111A (zh) 2011-05-17 2012-11-21 山东绿叶制药有限公司 一种多巴胺受体激动剂类药物的缓释制剂
WO2014205031A1 (fr) * 2013-06-19 2014-12-24 Map Pharmaceuticals, Inc. Formulation de rotigotine à libération prolongée
CN113730349B (zh) 2020-05-28 2025-10-31 四川科伦药物研究院有限公司 一种药物组合物及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000418A2 (fr) * 2006-06-27 2008-01-03 Sandoz Ag Nouveau procédé de préparation de sel
WO2019036624A1 (fr) * 2017-08-17 2019-02-21 Gu Zi Qiang Agents anti-parkinson de type sels de pamoate de monoamine, leur procédé de préparation et d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2022105644A1 *

Also Published As

Publication number Publication date
AU2021381638A9 (en) 2024-02-08
AU2021381638A1 (en) 2023-05-04
CN116367833B (zh) 2025-02-25
CN119930541A (zh) 2025-05-06
WO2022105644A1 (fr) 2022-05-27
JP2023550235A (ja) 2023-12-01
US20230365518A1 (en) 2023-11-16
EP4249476A1 (fr) 2023-09-27
US12583829B2 (en) 2026-03-24
CN116367833A (zh) 2023-06-30

Similar Documents

Publication Publication Date Title
EP4249476A4 (fr) Sel de composé benzothiazole, forme cristalline et son utilisation
EP3912976A4 (fr) Sel d'un inhibiteur d'egfr, forme cristalline et procédé de préparation associé
EP4352057A4 (fr) Nouveaux sels et cristaux
EP4059926A4 (fr) Forme cristalline de tafamidis ainsi que son procédé de préparation et son utilisation
EP3763713A4 (fr) Forme cristalline et forme saline de composé pyridoimidazole et son procédé de préparation
IL319797B1 (en) Method for synthesizing a furoimidazopyridine compound, a crystalline form of a furoimidazopyridine compound, and a crystalline form of a salt thereof
EP4190781A4 (fr) Sel et forme cristalline d'un composé de pyrimidine, et leurs procédés de préparation
EP3939978A4 (fr) Forme cristalline d'un inhibiteur de phosphodiestérase, son procédé de préparation et son utilisation
EP4464705A4 (fr) Sel d'un inhibiteur de rock, forme cristalline de sel, composition et utilisation pharmaceutique
EP3971170A4 (fr) Forme cristalline thermostable de haute pureté de composé 3-isoxazolidinone substitué, son procédé de préparation et son application
EP4063366A4 (fr) Forme cristalline d'un inhibiteur de nucléoprotéine et son utilisation
EP3854797A4 (fr) Forme cristalline d'un composé à trois cycles et utilisation associée
EP4438606A4 (fr) Nouvelle forme cristalline d'un composé nucléosidique et son sel
EP3985009A4 (fr) Forme cristalline b de composé de tétrahydrothiénopyridine, son procédé de préparation, composition et application
EP4269408A4 (fr) Forme cristalline d'un composé, son procédé de préparation et son utilisation
CA3291466A1 (fr) Forme cristalline de composé hétérocyclique, sel de celui-ci, forme cristalline de sel de celui-ci et utilisation
CA3298336A1 (fr) Sel de composé de thiazolopyrazine ou cristal de celui-ci et son utilisation
EP3845534A4 (fr) Forme de sel et forme cristalline d'un nouveau composé azatricyclique et utilisation associée
CA3260571A1 (fr) Composé benzothiazole et son utilisation
EP3909952A4 (fr) Sels de composé hétérocyclique et utilisation associée
HK40111131A (en) New crystal form of compound, and preparation method therefor and use thereof
HK40108063A (en) Novel salts and crystals
EP4458821A4 (fr) Forme saline et forme cristalline d'un composé de tétrahydrocyclohepta indazole
AU2020903196A0 (en) Salts and crystals
CA3297387A1 (fr) Forme cristalline d'un composé et son utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230320

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 53/126 20060101ALI20241112BHEP

Ipc: A61P 25/16 20060101ALI20241112BHEP

Ipc: A61K 31/428 20060101ALI20241112BHEP

Ipc: C07D 277/82 20060101AFI20241112BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20250314

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 53/126 20060101ALI20250310BHEP

Ipc: A61P 25/16 20060101ALI20250310BHEP

Ipc: A61K 31/428 20060101ALI20250310BHEP

Ipc: C07D 277/82 20060101AFI20250310BHEP